肿瘤免疫检查点抑制剂致免疫相关不良反应的预测标志物  

Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies

作　　者：唐辉 管梅[1] 孙昭[1] 白春梅[1] TANG Hui;GUAN Mei;SUN Zhao;BAI Chunmei(Department of Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China)

机构地区：[1]中国医学科学院,北京协和医学院,北京协和医院肿瘤内科,北京100730

出　　处：《中国医学科学院学报》2020年第6期825-830,共6页Acta Academiae Medicinae Sinicae

摘　　要：免疫检查点抑制剂(ICIs)对多种恶性肿瘤治疗有效,成为当今癌症治疗的革命性突破。虽然ICIs疗效确切,但也存在一些安全性的问题,其中主要是免疫相关不良反应(irAEs)。IrAEs与传统化疗药物及分子靶向药物相关不良反应不同,是由于ICIs治疗后免疫激活导致的不良反应,几乎可以累及全身各个系统。为了避免irAEs,找出其预测标志物成为一种迫切的需要,本文对预测ICIs治疗后irAEs的生物标志物进行综述。While immune checkpoint inhibitors(ICIs)are effective and promising treatments for a variety of malignancies,they also have safety concerns,especially the immune-related adverse events(irAEs).Unlike the side effects of traditional chemotherapy and targeted therapy,irAEs are adverse events caused by immune activation after ICIs treatment and thus may involve almost every system of the body.Therefore,biomarkers for predicting irAEs after ICIs treatment are urgently needed.Here we review the currently available predictive biomarkers of irAEs.

关 键 词：肿瘤 免疫检查点抑制剂 免疫相关不良反应 标志物 

分 类 号：R730.5[医药卫生—肿瘤]